January 4, 2018 09:28 AM EST
News Briefing

Biotech in­vestapalooza con­tin­ues with more ven­ture rounds for star­tups; Ova­Science cuts half of its work­force (again)

John Carroll

Editor & Founder

Ed­i­tor’s note: We here at End­points News pride our­selves on pro­vid­ing some com­pre­hen­sive ac­counts of all the ven­ture cash flow­ing in­to biotech com­pa­nies, but this …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times